pharm edaily

[Seungkwon kim, Edaily Reporter] Samsung Biologics, a leading contract development and manufacturing organization (CDMO), is set to participate in the 2025 BIO International Convention, the world’s largest biotech and pharmaceutical trade show, aiming to strengthen its global brand presence as Chinese rival Wuxi Biologics skips the event for a second year in a row.

The BIO International Convention, also known as BIO USA, is organized annually by the Biotechnology Innovation Organization (BIO) and rotates among major bioclusters across the United States. This year’s event will be held from June 16 to 19 at the Boston Convention and Exhibition Center, with more than 20,000 attendees expected.

An image of Samsung Biologics’ booth at the 2025 BIO International Convention. (Photo courtesy of Samsung Biologics)

Samsung Biologics, the only Korean company to maintain a solo booth at the event for 13 consecutive years since its founding in 2011, will once again take a prime location near the entrance of the exhibition hall. The company plans to set up a 167-square-meter booth equipped with LED walls and interactive touchscreens to showcase its latest capabilities.

The display will highlight the company’s CDMO competitiveness, including its cutting-edge digital transformation strategies and production capacity. Samsung Biologics will promote its recently operational fifth plant, which brings its total production volume to 784,000 liters one of the largest in the world.

The company also aims to draw attention to its expanded portfolio, which includes multispecific antibody development and production, the launch of its new antibody-drug conjugate (ADC) services, and artificial intelligence-powered operations.

Samsung Biologics will also deploy promotional banners at key locations throughout the convention center, including the main entrance, stairways, and skybridge, ensuring maximum visibility among attendees.

Through this strategic presence, the company aims to attract new clients and further expand its recognition and market share in the U.S. and broader global CDMO markets.